ArticleSignal transduction and targeted therapy2026
IFNAR1-dependent metabolic circuit drives pathogenic neutrophil activation in chronic mucosal inflammation.
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutrophils are double-edged effectors of the innate immune system: while essential for host defense, they can drive significant tissue damage in the context of chronic inflammatory diseases. Identifying strategies to selectively dampen their pathogenic functions without compromising antimicrobial immunity remains a major clinical challenge. Here, we define a conserved IFNAR1-driven circuit mediated by iron homeostasis that sustains neutrophil pathogenicity across distinct mucosal tissues. Using single-cell transcriptomics and a CRISPR-based functional screen, we identified the mitochondrial iron transporter Mitoferrin-1 (SLC25A37) as a key regulator of neutrophil inflammatory programming. Mechanistically, our data indicate that Mitoferrin-1 mediates a feedforward loop in which NET-derived histones activate toll-like receptor 9 (TLR9), which in turn sustains IFN-α/IFNAR1 signaling, rewires mitochondrial metabolism, and ultimately drives tissue damage through markedly increased of NETosis, reactive oxygen species production, and degranulation. Notably, this IFNAR1-driven inflammatory circuit operates entirely independently of antimicrobial function, as pharmacological IFNAR1 blockade fully preserves phagocytic activity against bacterial pathogens in vivo. Targeting this pathway selectively attenuates neutrophil-driven inflammation in both murine models of colitis and acute lung injury, as well as in primary human intestinal organoid systems. Together, these findings identify a targetable metabolic node for selectively disarming pathogenic neutrophil responses in the setting of chronic inflammatory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.